DK3393583T3 - Opløslig glycoprotein til behandling af trombotiske sygdomme - Google Patents
Opløslig glycoprotein til behandling af trombotiske sygdomme Download PDFInfo
- Publication number
- DK3393583T3 DK3393583T3 DK16826344.0T DK16826344T DK3393583T3 DK 3393583 T3 DK3393583 T3 DK 3393583T3 DK 16826344 T DK16826344 T DK 16826344T DK 3393583 T3 DK3393583 T3 DK 3393583T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- thrombotic diseases
- soluble glycoprotein
- glycoprotein
- soluble
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15202530.0A EP3184149A1 (de) | 2015-12-23 | 2015-12-23 | Lösliches glycoprotein v zur behandlung von thrombose-erkrankungen |
PCT/EP2016/082629 WO2017109212A1 (en) | 2015-12-23 | 2016-12-23 | Soluble glycoprotein v for treating thrombotic diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3393583T3 true DK3393583T3 (da) | 2020-08-10 |
Family
ID=55068852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16826344.0T DK3393583T3 (da) | 2015-12-23 | 2016-12-23 | Opløslig glycoprotein til behandling af trombotiske sygdomme |
Country Status (12)
Country | Link |
---|---|
US (1) | US11028144B2 (de) |
EP (2) | EP3184149A1 (de) |
JP (1) | JP7016536B2 (de) |
KR (1) | KR20180091929A (de) |
CN (1) | CN108472503A (de) |
AU (1) | AU2016375187C1 (de) |
BR (1) | BR112018012295A2 (de) |
CA (1) | CA3008196A1 (de) |
DK (1) | DK3393583T3 (de) |
ES (1) | ES2805318T3 (de) |
SG (2) | SG11201804410YA (de) |
WO (1) | WO2017109212A1 (de) |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
AU7325794A (en) * | 1993-07-09 | 1995-02-06 | Cor Therapeutics, Inc. | Platelet glycoprotein v gene and uses |
US6083688A (en) * | 1993-07-09 | 2000-07-04 | Cor Therapeutics, Inc | Platelet glycoprotein V gene and uses |
US5770575A (en) * | 1994-03-16 | 1998-06-23 | Ortho Pharmaceutical Corporation | Nipecotic acid derivatives as antithrombotic compounds |
JPH11501506A (ja) | 1994-12-12 | 1999-02-09 | ベス イスラエル デアコネス メディカル センター | キメラ型サイトカインおよびその利用 |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
WO2002017711A2 (en) * | 2000-08-31 | 2002-03-07 | Cor Therapeutics, Inc. | Therapeutics and diagnostics based on a novel signal transduction system in platelets |
EP1572936A2 (de) | 2002-03-05 | 2005-09-14 | Eli Lilly And Company | Heterologe g-csf-fusionsproteine |
AU2004239244C1 (en) | 2003-05-06 | 2015-04-23 | Bioverativ Therapeutics Inc. | Clotting factor-Fc chimeric proteins to treat hemophilia |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
ATE525395T1 (de) | 2003-06-12 | 2011-10-15 | Lilly Co Eli | Fusions proteine von glp-1-analoga |
CN1902222A (zh) | 2003-12-31 | 2007-01-24 | 默克专利有限公司 | 具有改善药物代谢动力学的Fc-促红细胞生成素融合蛋白质 |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
EP1816201A1 (de) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät |
US9458223B2 (en) | 2012-02-15 | 2016-10-04 | Csl Behring Gmbh | Von willebrand factor variants having improved factor VIII binding affinity |
-
2015
- 2015-12-23 EP EP15202530.0A patent/EP3184149A1/de not_active Withdrawn
-
2016
- 2016-12-23 DK DK16826344.0T patent/DK3393583T3/da active
- 2016-12-23 EP EP16826344.0A patent/EP3393583B1/de active Active
- 2016-12-23 WO PCT/EP2016/082629 patent/WO2017109212A1/en active Application Filing
- 2016-12-23 CA CA3008196A patent/CA3008196A1/en active Pending
- 2016-12-23 CN CN201680075541.8A patent/CN108472503A/zh active Pending
- 2016-12-23 US US16/065,365 patent/US11028144B2/en active Active
- 2016-12-23 SG SG11201804410YA patent/SG11201804410YA/en unknown
- 2016-12-23 KR KR1020187021243A patent/KR20180091929A/ko not_active Application Discontinuation
- 2016-12-23 ES ES16826344T patent/ES2805318T3/es active Active
- 2016-12-23 BR BR112018012295A patent/BR112018012295A2/pt active Search and Examination
- 2016-12-23 SG SG10201911567VA patent/SG10201911567VA/en unknown
- 2016-12-23 AU AU2016375187A patent/AU2016375187C1/en active Active
- 2016-12-23 JP JP2018533222A patent/JP7016536B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
KR20180091929A (ko) | 2018-08-16 |
SG11201804410YA (en) | 2018-07-30 |
BR112018012295A2 (pt) | 2019-02-05 |
EP3184149A1 (de) | 2017-06-28 |
SG10201911567VA (en) | 2020-01-30 |
US20190169265A1 (en) | 2019-06-06 |
JP2019504037A (ja) | 2019-02-14 |
JP7016536B2 (ja) | 2022-02-07 |
CA3008196A1 (en) | 2017-06-29 |
CN108472503A (zh) | 2018-08-31 |
US11028144B2 (en) | 2021-06-08 |
AU2016375187B2 (en) | 2022-08-11 |
AU2016375187C1 (en) | 2022-11-24 |
EP3393583A1 (de) | 2018-10-31 |
EP3393583B1 (de) | 2020-05-13 |
AU2016375187A1 (en) | 2018-06-14 |
WO2017109212A1 (en) | 2017-06-29 |
ES2805318T3 (es) | 2021-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3785717T3 (da) | Fremgangsmåder til behandling af coronaviridae-infektioner | |
DK3192902T3 (da) | Fremgangsmåde til fremstilling af graphenholdige viscosefibre | |
DK3288581T3 (da) | Fremgangsmåde til behandling af cancer | |
DK3173092T3 (da) | Rna-holdig sammensætning til behandling af tumorsygdomme | |
DK3521282T3 (da) | Quinazolinderivater anvendt til behandling af hiv | |
DK3096741T3 (da) | Fremgangsmåde til fremstillingen af hybridosomer | |
DK3556775T3 (da) | Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter | |
DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
DK3492632T3 (da) | Metoder til behandling af lithiumholdige materialer | |
DK3466432T3 (da) | Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner | |
DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
DK3072835T3 (da) | Fremgangsmåde til fremføring | |
DK3325443T3 (da) | Fremgangsmåde til fremstilling af pridopidin | |
DK3174858T3 (da) | Fremgangsmåde til fremstilling af pyrazoler | |
DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
DK3169328T3 (da) | Quinolinderivater til behandling af inflammationssygdomme | |
DK3265087T3 (da) | Fremgangsmåde til behandling med tradipitant | |
DK3524255T3 (da) | Sammensætning til behandling af acne | |
DK3157534T3 (da) | Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande | |
DK3280408T3 (da) | Fremgangsmåde til fremstilling af dicycloplatin | |
DK3430143T3 (da) | Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme | |
DK3166611T3 (da) | Fremgangsmåde til fremstilling af 4-alkoxy-3-hydroxypicolinsyrer | |
DK3261661T3 (da) | Menotropin til behandling af infertilitet | |
DK3468604T3 (da) | Farmaceutiske kombinationer til behandling af cancer |